BR112018067586A2 - composição administrável oralmente - Google Patents

composição administrável oralmente

Info

Publication number
BR112018067586A2
BR112018067586A2 BR112018067586A BR112018067586A BR112018067586A2 BR 112018067586 A2 BR112018067586 A2 BR 112018067586A2 BR 112018067586 A BR112018067586 A BR 112018067586A BR 112018067586 A BR112018067586 A BR 112018067586A BR 112018067586 A2 BR112018067586 A2 BR 112018067586A2
Authority
BR
Brazil
Prior art keywords
orally administrable
composition
micelle
administrable composition
pharmaceutically acceptable
Prior art date
Application number
BR112018067586A
Other languages
English (en)
Inventor
Modi Pankaj
Original Assignee
Ctt Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59722571&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018067586(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ctt Pharma Inc filed Critical Ctt Pharma Inc
Publication of BR112018067586A2 publication Critical patent/BR112018067586A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

composição administrável oralmente é fornecida uma composição micelar administrável oralmente. a composição compreende um agente farmacêutico encapsulado em micelas formadas por pelo menos um composto formador de micelas em um solvente aquoso farmaceuticamente aceitável compreendendo um salicilato de metal alcalino e um edetato farmaceuticamente aceitável combinados com pelo menos um agente formador de película fisiologicamente aceitável.
BR112018067586A 2016-03-03 2017-02-27 composição administrável oralmente BR112018067586A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/059,444 US11166912B2 (en) 2016-03-03 2016-03-03 Orally administrable composition
PCT/CA2017/050250 WO2017147691A1 (en) 2016-03-03 2017-02-27 Orally administrable composition

Publications (1)

Publication Number Publication Date
BR112018067586A2 true BR112018067586A2 (pt) 2019-01-08

Family

ID=59722571

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018067586A BR112018067586A2 (pt) 2016-03-03 2017-02-27 composição administrável oralmente

Country Status (11)

Country Link
US (1) US11166912B2 (pt)
EP (1) EP3423037A4 (pt)
AU (1) AU2017225927B2 (pt)
BR (1) BR112018067586A2 (pt)
CL (1) CL2018002474A1 (pt)
CO (1) CO2018010549A2 (pt)
CU (1) CU20180097A7 (pt)
IL (1) IL261479B2 (pt)
PE (1) PE20190318A1 (pt)
WO (1) WO2017147691A1 (pt)
ZA (1) ZA201805802B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033493B2 (en) 2013-12-02 2021-06-15 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
EP3222292A1 (en) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
US20220079881A1 (en) * 2016-03-03 2022-03-17 Ctt Pharma Inc. Orally Administrable Composition
WO2018075730A1 (en) * 2016-10-21 2018-04-26 Axim Biotechnologies, Inc. Suppositories comprising cannabinoids
WO2019195355A1 (en) * 2018-04-03 2019-10-10 Pure Green Tablet or composition having n-acyl ethanolamine and cannabinoid
US20190336457A1 (en) * 2018-04-18 2019-11-07 Leading Edge Pharms Inc. Compositions and methods for alleviating pain
US11185526B2 (en) 2018-09-04 2021-11-30 Babak Ghalili Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods
US10751299B2 (en) * 2018-09-04 2020-08-25 Babak Ghalili Cannabinoid and menthol compositions and methods
US11602504B2 (en) 2018-11-05 2023-03-14 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
US10588871B1 (en) 2019-06-28 2020-03-17 Nexzol Pharma, Inc. Transdermal formulation for the treatment of pain and/or inflammation
CN112569220B (zh) * 2019-09-30 2023-03-07 云南汉盟制药有限公司 四氢次大麻酚在制备用于治疗肺动脉高压药物中的应用及含有四氢次大麻酚的药物组合物
GB2587621A (en) * 2019-09-30 2021-04-07 Biofilm Ltd Oral films and a methods for the manufacture and delivery thereof
CN111117125A (zh) * 2019-12-30 2020-05-08 武汉轻工大学 一种复合抗菌膜及其制备方法
CN113116868B (zh) * 2019-12-31 2022-08-19 汉义生物科技（北京）有限公司 四氢次大麻酚在肺动脉高压的预防和/或治疗中的应用
WO2021243188A1 (en) * 2020-05-29 2021-12-02 Hemp Synergistics Powderized cannabis oil
US11786475B2 (en) * 2020-07-22 2023-10-17 Soluble Technologies Inc. Film-based dosage form
WO2022027053A1 (en) * 2020-07-28 2022-02-03 Wsmef, Llc Micelle preparations of full-spectrum hemp oil for treating type ii diabetes, reducing inflammation during covid-19, and improving sleep quality
US20240041903A1 (en) 2020-12-09 2024-02-08 I+Med S. Coop. Composition Comprising Sea Water and Cannabinoid Loaded Submicroparticles for Pharmaceutical, Nutraceutical and Cosmetic Applications
WO2023039587A2 (en) * 2021-09-13 2023-03-16 Arriaga Adan Cannabinoid composition and method of using the same
US20230329354A1 (en) * 2022-04-15 2023-10-19 Air 2 LLC Aerosol pressurized inhalation delivery device and methods for manufacture and use of the same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117773A (en) * 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US6221378B1 (en) 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US6350458B1 (en) * 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
CA2229286C (en) 1998-02-10 2005-07-26 Generex Pharmaceuticals Inc. Mixed micellar delivery system and method of preparation
US6312665B1 (en) 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
US6849263B2 (en) * 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
AU4445201A (en) * 2000-03-30 2001-10-08 Generex Pharmaceuticals Inc. Method for administering insulin to the buccal region
EA006079B1 (ru) 2000-03-31 2005-08-25 Пфайзер Продактс Инк. Новые пиперазиновые производные
US6398589B1 (en) 2000-09-07 2002-06-04 Richard A. Congelliere Device for restricting operation of an electrical tool
AU2002952597A0 (en) 2002-11-11 2002-11-28 Schering-Plough Pty. Limited Topical parasiticide formulations and methods of treatment
AU2005338631B2 (en) 2005-11-30 2011-12-01 Generex Pharmaceuticals Inc. Orally absorbed pharmaceutical formulation and method of administration
WO2009015456A1 (en) 2007-07-30 2009-02-05 Generex Pharmaceuticals Inc. Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray
CA2624110C (en) 2008-03-27 2010-11-09 Pankaj Modi A rapidly-dissolving orally administrable wafer formulation
US8623401B2 (en) * 2008-03-27 2014-01-07 Fenwafe Inc. Wafer formulation
WO2010002418A2 (en) 2008-07-01 2010-01-07 The Johns Hopkins University Quick-dissolving oral thin film for targeted delivery of therapeutic agents
US8808734B2 (en) 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
AU2014347807A1 (en) 2013-10-31 2016-05-26 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations

Also Published As

Publication number Publication date
IL261479B2 (en) 2023-09-01
EP3423037A4 (en) 2019-11-27
EP3423037A1 (en) 2019-01-09
IL261479A (en) 2021-03-25
AU2017225927A1 (en) 2018-10-04
PE20190318A1 (es) 2019-03-04
US20170252300A1 (en) 2017-09-07
CU20180097A7 (es) 2019-05-03
WO2017147691A1 (en) 2017-09-08
AU2017225927B2 (en) 2021-07-01
CL2018002474A1 (es) 2019-01-18
IL261479A0 (en) 2018-10-31
ZA201805802B (en) 2019-06-26
IL261479B1 (en) 2023-05-01
US11166912B2 (en) 2021-11-09
CO2018010549A2 (es) 2018-12-14

Similar Documents

Publication Publication Date Title
BR112018067586A2 (pt) composição administrável oralmente
CO2019008364A2 (es) Composiciones farmacéuticas que comprenden meloxicam
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
WO2016131067A3 (en) Pharmaceutical compositions comprising meloxicam
MX2021009475A (es) Composiciones farmaceuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
AR081542A1 (es) Composiciones de emulsiones farmaceuticas con bajo contenido de aceite que comprenden un progestageno
BR112015023754A2 (pt) artigo de liga de titânio nanoestruturada, e, método para fabricar uma liga de titânio nanoestruturada
NZ631100A (en) Soft chewable pharmaceutical products
MX2021010359A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
CU24486B1 (es) Dispersión sólida amorfa que comprende taxano, tabletas comprendiendo la misma y método para prepararla
MX2016008429A (es) Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria.
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
BR112018068116A2 (pt) película transmucosal para administração de montelucaste
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
MY191219A (en) Therapeutic agent for fibrosis
BR112017019364A2 (pt) dispersões sólidas
PE20151282A1 (es) Combinacion de medicamentos que comprenden fenilefrina y paracetamol
IL264538B2 (en) A new use of n,n-bis-2-mercaptoethyl isophthalamide
WO2019004984A3 (en) PHARMACEUTICAL FORMULATION COMPRISING CHOLECALCIFEROL
CL2017003465A1 (es) Uso combinado de bumetanida con ácido valproico o una de sus sales farmacéuticamente aceptables para restablecer la homeostasis de cl- y con ello, permitir la preparación de un fármaco efectivo en el tratamiento de la epilepsia, y especialmente, en el tratamiento de la epilepsia refractaria.
ES2475942B1 (es) Composición farmacéutica de citrato de sildenafilo en forma de solución acuosa
BR112016006485A2 (pt) composições de liberação pulsátil revestidas por compressão
AR099330A1 (es) Uso de paricalcitol en el tratamiento de la anemia inflamatoria
BR112016029417A8 (pt) composição farmacêutica que compreende desmopressina, uso de uma ou mais gomas para aumentar sua estabilidade, película de desintegração oral e seu método de preparação
WO2013136346A3 (en) Taste masking pharmaceutical orally dissolving strips of lornoxicam

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time